

Darunavir-Cobicistat vs standard treatment

Author(s): Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M

Question: Should Darunavir/Cobicistat vs standard treatment be used for COVID-19?

Setting: inpatient

Certainty assessment							No of patients		Effect		Certainty	Importance
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Darunavir/Cobicistat	Trattamento standard	Relative (95% CI)	Absolute (95% CI)		

Mortality, any causes (follow up: 14 days)

1 ¹	randomised trials	serious ^a	not serious	not serious	very serious ^b	none	No deaths at 14 days				⊕○○○ VERY LOW	
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	----------------------	--	--	--	------------------	--

SARS-CoV-2 clearance at 7 days

1 ¹	randomised trials	serious ^a	not serious	not serious	very serious ^b	none	7/15 (46.7%)	9/15 (60.0%)	RR 0.78 (0.39 to 1.54)	132 fewer per 1.000 (from 366 fewer to 324 more)	⊕○○○ VERY LOW	
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	--------------	--------------	----------------------------------	--	------------------	--

Time to SARS-CoV-2 clearance

1 ¹	randomised trials	serious ^a	not serious	not serious	very serious ^b	none	The study reports that time of SARS-CoV-2 clearance does not differ between the two groups (median, 8 days vs 7 days); HR: 0.82 95% CI (0.36–1.88) p=0.64				⊕○○○ VERY LOW	
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	--	--	--	--	------------------	--

Certainty assessment							Nº of patients		Effect		Certainty	Importance
Nº of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Darunavir/Cobicistat	Trattamento standard	Relative (95% CI)	Absolute (95% CI)		

Number of patients any adverse event

1 ¹	randomised trials	serious ^a	not serious	not serious	very serious ^b	none	8/15 (53.3%)	7/15 (46.7%)	RR 1.14 (0.56 to 2.35)	65 more per 1.000 (from 205 fewer to 630 more)	⊕○○○ VERY LOW	
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	--------------	--------------	----------------------------------	--	------------------	--

Progression of COVID-19 disease

1 ¹	randomised trials	serious ^a	not serious	not serious	very serious ^b	none	1/15 (6.7%)	0/15 (0.0%)	RR 3.00 (0.13 to 68.26)	0 fewer per 1.000 (from 0 fewer to 0 fewer)	⊕○○○ VERY LOW	
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	-------------	-------------	-----------------------------------	---	------------------	--

CI: Confidence interval; RR: Risk ratio; HR: Hazard Ratio

Explanations

- a. Downgraded of one level because high risk of performance bias and unclear risk of selection bias;
- b. Downgraded of two level for small sample size (<200)

References

1. Chen, Jun, Xia, Lu, Liu, Li, Xu, Qingnian, Ling, Yun, Huang, Dan, Huang, Wei, Song, Shuli, Xu, Shuibao, Shen, Yingzhong, Lu, Hongzhou. Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19. Open Forum Infectious Diseases; 2020.